Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
Overview
To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: June 10, 2020
Detailed Description
Clinical inertia in intensifying treatment of type 2 diabetes patients occurs in the range of 70% in numerous real world database assessments. The investigator proposes treating patients with Afrezza who have an index HbA1c between 7.5% and 11.5% despite being treated with diabetes medications for at least 6 months. The response to Afrezza will be assessed with Continuous Glucose Monitoring Systems (CGMS) studies and initial and follow-up HbA1cs. The goal is to assess how the investigator can rapidly and safely initiate intensification in this patient population, where extensive delays in HbA1c improvement often occur.
Interventions
- Drug: Afrezza Inhalant Product
- Mealtime Ultra-Rapid Acting Insulin
Arms, Groups and Cohorts
- Other: Afrezza Inhalant Product
- Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
Clinical Trial Outcome Measures
Primary Measures
- Percentage change from baseline HbA1c
- Time Frame: 3 months
- Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications.
Secondary Measures
- Percentage of patients having HbA1c under 7%
- Time Frame: 3 months
- Demonstrate that the addition of mealtime Afrezza can significantly lower HbA1c within 3 months in uncontrolled type 2 diabetes patients initially having HbA1c of 7.5 or higher, despite at least 6 months of prior therapy with diabetes medications.
- Percent of time that Blood glucose (BG) is under 70 mg/dL on CGMS
- Time Frame: 3 months
- Demonstrate that the addition of mealtime Afrezza can lower blood glucose in uncontrolled type 2 diabetes patients.
Participating in This Clinical Trial
Inclusion Criteria
- Adult type 2 diabetes patients age 18 or older – HbA1c ≥ 7.5% and ≤ 11.5% after at least 6 months treatment with diabetes medication. Treatment may include oral agents, basal insulin or GLP-1 in any combination. – Patient and provider agree not to add additional diabetes medications during the 14 weeks of the study (unless rescue treatment is indicated). Exclusion Criteria:
- History of asthma, COPD or smoking within 6 months – FEV1 under 70% predicted – Pregnancy – Active malignancies and/or life expectancy of < 12 months – Major surgery planned during study period – Currently using rapid acting insulins – Novolog, Humalog, Apidra – Prior use of Afrezza in the last 3 months – Unwilling to test blood glucose before or after each meal – Exposure to systemic glucocorticoids within 6 weeks of screening – Severe hypoglycemia in last 6 months or hypoglycemia unawareness – Any medical condition which, in the opinion of the PI, would interfere with ability to understand or respond to the administration of inhaled insulin
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Model Clinical Research LLC
- Collaborator
- Mannkind Corporation
- Provider of Information About this Clinical Study
- Principal Investigator: Philip Levin, Senior Director of Clinical Research – Model Clinical Research LLC
- Overall Official(s)
- Philip Levin, MD, Principal Investigator, Senior Director of MODEL Clinical Research
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.